ABSTRACT
Psoriasis is a systematic chronic disease with large influence on patients' quality of life (QoL). The aim of this study was to assess the QoL of patients with psoriasis using generic, dermatology-specific and psoriasis-specific instruments simultaneously, to investigate the relationships between dimensions or subscales of the questionnaires and to identify categories of patients at risk of a high QoL impairment. The study comprised 100 consecutive patients with psoriasis treated at the Department of Dermatology, Clinical Center "Zvezdara", Belgrade, from January to December 2011. Three QoL questionnaires were administered: the EuroQol-5D (EQ-5D), the Dermatological Life Quality Index (DLQI) and the Psoriasis Disability Index (PDI). The Psoriasis Area and Severity Index was used in evaluating disease severity. According to our results the QoL of psoriatic patients was impaired (the overall DLQI and PDI scores were 10.5 ± 7.2 and 13.4 ± 8.7, respectively, while EQ visual analog scale score was 48.8 ± 25.1). The most predictive factor of QoL impairment was disease severity, followed by sole and nail involvement. Psoriatic arthritis and bleeding were also associated with impaired QoL. Significant correlations between the instruments used in this study were in the expected directions. Mainly strong and moderate significant correlations ranging 0.26-0.84 were seen between DLQI and PDI instruments. A detailed approach to QoL assessment may give to the dermatologist useful information that could be of help in identifying patients belonging to categories at risk of high QoL impairment due to psoriasis, thus guiding them in clinical practice.
Subject(s)
Psoriasis/psychology , Adult , Female , Humans , Linear Models , Male , Middle Aged , Quality of Life , Self ReportABSTRACT
The role of xanthine oxidase (XOD) in patients undergoing chronic hemodialysis treatment (HD) is poorly understood. Geriatric nutritional risk index (GNRI) ≤ 90 could be linked with malnutrition-inflammation complex syndrome. This study measured XOD, myeloperoxidase (MPO), superoxide dismutase (SOD), lipid hydroperoxides, total free thiol groups, and advanced oxidation protein products (AOPP) in 50 HD patients before commencing (pre-HD) and immediately after completion of HD session (post-HD) and in 22 healthy controls. Pre-HD serum hydroperoxides, AOPP, XOD, and SOD were higher and total thiol groups were lower in patients than in controls (P < 0.05, resp.). Compared to baseline values, serum MPO activity was increased irrespective of GNRI status. Serum XOD activity was increasing during HD treatment in the group with GNRI ≤ 90 (P = 0.030) whilst decreasing in the group with GNRI > 90 (P = 0.002). In a multiple regression analysis, post-HD serum XOD activity was independently associated with GNRI ≤ 90 ( ß ± SE: 0.398 ± 0.151; P = 0.012) and HD vintage ( ß ± SE: -0.349 ± 0.139; P = 0.016). These results indicate that an upregulated XOD may be implicated in HD-induced oxidative injury contributing to accelerated protein damage in patients with GNRI ≤ 90.
Subject(s)
Nutritional Status , Oxidative Stress , Renal Dialysis , Xanthine Oxidase/metabolism , Antioxidants/metabolism , Biomarkers/blood , Case-Control Studies , Female , Humans , Kidney Failure, Chronic/blood , Kidney Failure, Chronic/enzymology , Kidney Failure, Chronic/pathology , Male , Middle Aged , Multivariate Analysis , Peroxidase/blood , Regression Analysis , Superoxide Dismutase/blood , Xanthine Oxidase/bloodABSTRACT
Olive leaf extract (OLE) possesses, among other, antioxidative properties, but whether it influences gastroprotection against stress-induced gastric lesions remains unknown. In this study we investigated the protective effect of OLE, a natural antioxidant, on gastric mucosal damage induced by cold restraint stress (CRS) in rats. Three different doses of commercial OLE EFLA((R)) 943 were applied intragastrically (i.g.) 30 min prior to stress induction. Macroscopic gastric lesions were evaluated and ulcer index (UI) was calculated. Histological evidence of gastric mucosal lesions was also obtained. Concentration of malondialdehyde (MDA) as an index of lipid peroxidation, and catalase (CAT) and superoxide dismutase (SOD) activities were determined in gastric mucosa. The effects of applied OLE on gastric mucosal lesions, lipid peroxidation and antioxidative enzymes activity were compared with effects of i.g. pretreatment of reference drug, ranitidine. CRS caused severe gastric lesions in all non-pretreated animals, and this finding was confirmed histologicaly. Pretreatment with OLE (40, 80 and 120 mg.kg(-1)), as well as with ranitidine (50 mg.kg(-1)), significantly (p < 0.001) attenuated stress-induced gastric lesions. Treatment with 80 mg.kg(-1) of OLE was the most effective in prevention of rise in gastric MDA level and decrease in CAT and SOD activity. The results obtained indicate that OLE possesses gastroprotective activity against CRS-induced gastric lesions in rats, possibly related to its antioxidative properties.
Subject(s)
Cold Temperature , Olea/chemistry , Plant Extracts/pharmacology , Plant Leaves/chemistry , Stomach Ulcer/etiology , Stomach Ulcer/prevention & control , Stress, Psychological/complications , Animals , Antioxidants/metabolism , Enzymes/metabolism , Gastric Mucosa/drug effects , Gastric Mucosa/enzymology , Gastric Mucosa/metabolism , Gastric Mucosa/pathology , Lipid Peroxidation/drug effects , Male , Rats , Rats, Wistar , Restraint, Physical , Stomach Ulcer/metabolism , Stomach Ulcer/pathology , SuspensionsABSTRACT
The aim of this work was to investigate the effect on antioxidant potential of some commonly used drugs (morphine, tramadol, bromocriptine, haloperidol and azithromycin) on immobilization stress (IS) combined with cold restraint stress (CRS) in the rat. After the drug treatment the animals were kept immobilized in the cold chamber at 4+/-0.3 degrees C for 3 hours and then decapitaed and the livers were extracted. The following parameters were determined in the liver homogenate: content of reduced glutathione, activities of catalase, xanthine oxidase, glutathione reductase, glutathione peroxidase, peroxidase, and lipid peroxidation intensity. A battery of biochemical assays was used and the resulting data were statistically analyzed. Combined stress exhibited a prooxidative action (increased catalase activity, lowered content of reduced glutathione). Significantly enhanced catalase activity that was observed in all groups compared to the control indicates that the primary reactive oxygen species (ROS) metabolite is hydrogen peroxide, which decomposes very rapidly (very high catalase activity), thus hindering formation of OH radicals as the most toxic ROS. None of the tested drugs showed a protective effect on combined IS and CRS. The intensity of lipid peroxidation did not change either in the combined stress or under additional influence of the drugs. Probably, under our experimental conditions, the time was not sufficiently long to observe damage of lipid membrane by ROS.
Subject(s)
Antioxidants/pharmacology , Antioxidants/therapeutic use , Cold Temperature , Immobilization/physiology , Oxidative Stress/drug effects , Stress, Physiological/physiology , Animals , Azithromycin/therapeutic use , Bromocriptine/therapeutic use , Catalase/metabolism , Glutathione/metabolism , Glutathione Peroxidase/metabolism , Glutathione Reductase/metabolism , Haloperidol/therapeutic use , Hydrogen Peroxide/metabolism , Lipid Peroxidation/drug effects , Male , Morphine/therapeutic use , Rats , Rats, Wistar , Reactive Oxygen Species/metabolism , Tramadol/therapeutic useABSTRACT
INTRODUCTION: In some cases of multicystic forms of liver echinococcal disease, the advanced method for treatment of cystic echinococcosis faces great problems relating to the final outcome of the treatment. CASE REPORT: In May 2005, a computerized tomography of the abdomen obtained in a 27-year-old female patient with abdominal pain revealed more than 20 echinococcal cysts measuring up to 6.7 cm in both lobes of the liver. Laboratory analyses found the value of eosinophils 6.8%, gamma globulins 29.9%, immunoglobulin E 29 600 IU/mL and the indirect hemagglutination for echinococcosis 1:8,196. The treatment started in December that year with the continuous administration of a daily dose of 800 mg (14.5 mg/kg body weight) of albendazole, but it was terminated two months later due to high serum transaminases values. By the end of 2006, the largest cyst detected in the left lobe of the liver had a diameter of 5.7 cm and the one in the right lobe of the liver measured 4.1 cm. There were lesions of germinative membrane found on both cysts. Six months later, praziquantel at daily dose of 2,500 mg (45.3 mg/kg body waight) was introduced into the therapy, but the treatment was terminated after eight days because of the development of exanthema. The computerized tomography of the abdomen obtained in February 2008 revealed the presence of a large number of echinococcal cysts in the liver. The largest among those cysts measured 3.5 cm while calcifications of the cyst walls were observed on some of them. None of the remaining therapeutic options for further treatmetnt of echinococcal disease could be applied. CONCLUSION: The presented case confirms medical therapy as the only option for the treatment of some forms of cystic echinococcosis. Benzimidazole carbamates (albendazole, mebendazole) and praziquantel are only efficacious antihelminitics currently available, and when they have to be withdrawn due to serious adverse affects, futher treatment of a patient with liver multicystic echinococcosis is impossible. Because of that there is a need to search for new and more efficient drugs for the treatment of ehinococcal disease.
Subject(s)
Anthelmintics/adverse effects , Echinococcosis, Hepatic/drug therapy , Adult , Anthelmintics/therapeutic use , Echinococcosis, Hepatic/pathology , Female , HumansABSTRACT
The aim of this work was to investigate the antioxidant potential of some commonly used drugs (bromocriptine, haloperidol and azithromycin) on alcohol-induced ulcers in the rat. The following parameters were determined: content of reduced glutathione, activities of catalase, xanthine oxidase, glutathione reductase, glutathione peroxidase, peroxidase, and lipid peroxidation intensity. A battery of biochemical assays were used and the resulting data was statistically analyzed. Alcohol stress caused gastric ulcerations and hemorrhages and changed all the examined parameters except glutathione peroxidase activity. All drugs reduced the ulcer index and hemorrhages, with azithromycin showing the strongest effects. The drugs in combination with alcohol showed different effects on biochemical parameters. Our results indicate that the gastroprotective effects of the investigated drugs on experimental lesions induced by 100% ethanol could not be correlated with their antioxidative properties.
Subject(s)
Antioxidants/therapeutic use , Ethanol/adverse effects , Stomach Ulcer/chemically induced , Stomach Ulcer/drug therapy , Animals , Anti-Bacterial Agents/pharmacology , Antioxidants/metabolism , Azithromycin/pharmacology , Bromocriptine/pharmacology , Dopamine Agonists/pharmacology , Dopamine Antagonists/pharmacology , Haloperidol , Humans , Lipid Peroxidation , Male , Oxidative Stress , Rats , Rats, Wistar , Stomach/drug effects , Stomach/pathology , Stomach Ulcer/pathologyABSTRACT
The major aim of this work was to investigate how alcohol-induced oxidative stress in combined chemotherapy changes the metabolic function of the liver in experimental animals. This research was conducted to establish how bromocriptine, haloperidol and azithromycin, applied to the experimental model, affected the antioxidative status of the liver. The following parameters were determined: reduced glutathione, activities of glutathione peroxidase, glutathione reductase, peroxidase, catalase, xanthine oxidase and lipid peroxidation intensity. Alanine transaminase was measured in serum. Alcohol stress (AO group) reduced glutathione and the activity of xanthine oxidase and glutathione peroxidase, but increased catalase and alanine transaminase activity. The best protective effect was achieved with the bromocriptine (AB1 group), while other groups had similar effects on the studied parameters.
Subject(s)
Ethanol/toxicity , Liver/drug effects , Oxidative Stress/drug effects , Alanine Transaminase/metabolism , Animals , Azithromycin/pharmacology , Bromocriptine/pharmacology , Catalase/metabolism , Glutathione/metabolism , Glutathione Reductase/metabolism , Haloperidol/pharmacology , Lipid Peroxidation/drug effects , Liver/metabolism , Male , Peroxidase/metabolism , Rats , Rats, Wistar , Xanthine Oxidase/metabolismABSTRACT
BACKGROUND/AIM: Modern treatment of cystic echinococcosis, except for surgical treatment and percutaneous drainage of cyst considers also administration of albendazole as a type of individual therapy. However, clinicians fear of the serious adverse effects of high doses of albendazole, first of all the elevation of serum transaminases activity, very frequently results in subdosing of albendazole and wrong conclusions its efficacy and safety. The aim of this study was to investigate adverse effects of a longterm, continual administration of high doses of albendazole in the treatment of patients with echinococcal disease. METHODS: A total of 42 patients (mean age 40.4 +/- 18.3 years) with echinococcal disease were included in the study. They were treated with continual administration of high doses of albendazole within the period of 4 to 6 months. The subgroups of 27 and 15 patients were treated with 15-20 mg/kg/day and with 21-25 mg/kg/day albendazole, respectively. The patients in the control group (18 with surgical treatment, 6 with percutaneous drainage of cyst) were treated with 800 mg albendazole per day (< 15 mg/kg body weight) in the cycles of 28 days (1-3 cycles) and a two-week pause between them. RESULTS: In the study group adverse effects of albendazole were registered in 20 (47.6%), whereas in the control group in 6 (30.0%) of the patients. In both subgroups elevated activity of serum transaminases were found more frequently in the study group compared to the control one (35.7% vs 25%, p < 0.05), especially in the patients who were treated with higher doses of albendazole. The patients in the study group, compared to the patients in the control group had significantly higher mean activity of serum alanin aminotransferase in the course of the second and third month of the therapy (p < 0.05). Administration of albendazole due to adverse effects was stopped in 3 (7.1%) of the patients in the study group. Two (4.8%) of them had a very high activity of serum transaminases and one had a muscle pains and high activity of serum creatine kinase. After the interruption of the therapy we documented a nonnalization of serum enzyme levels in all the patients. CONCLUSION: Longterm, continual administration of high doses of albendazole in the patients with echinococcal disease results in significant elevation of serum transaminases activity, compared to the patients treated with albendazole in the cycles, but in the majority of the patients serum transaminases activity was normalizated by the end of a 6-month period.